Compare Incyte Corporation (INCY) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Koninklijke Philips NV — how do they compare? Incyte Corporation trades at $120.5 (market cap $24.54B), while Koninklijke Philips NV trades at $26.81 (market cap $26.58B). The key difference: Incyte Corporation and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays a 3.75% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PHG | |
|---|---|---|
Market Cap | $24.54B | $26.58B |
Sector | Health | Health |
52-Week High | $129.93 | $32.91 |
52-Week Low | $81.61 | $25.02 |
Enterprise Value | $20.04B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.
The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
